Alvogen Aims To Be First On EU Pazopanib
Rival To Novartis’ Votrient Filed For Several European Markets
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.
You may also be interested in...
Just months ahead of the patent expiry for Votrient in India, Novartis hauls alleged infringer MSN Laboratories to court, which has bound the Indian firm by its pre-launch assurance for the anticancer therapy.
Alvogen is claiming the first European launch of a rival to Pierre Fabre’s Navelbine in Europe, through the generics firm’s Lotus Pharmaceuticals subsidiary.
As Prestige BioPharma announced plans for Phase I and Phase III trials of its PBP1502 proposed adalimumab biosimilar, as well as expected filing dates in the EU and US, the company outlined how it believes its proprietary technology will allow its Humira rival to compete aggressively on price.